Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture

Journal of Clinical Investigation

Volumn 100, Issue 10, 1997, Pages 2596-2605

  Imai, Yumi ^a   Busby Jr , Walker H ^a   Smith, Christine E ^b   Clarke, Jane B ^a   Garmong, Aaron J ^a   Horwitz, Gayle D ^a   Rees, Catherine ^a   Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

Atherosclerosis; IGF I receptor; Serine protease; Smooth muscle cell migration; Somatomedin C

Indexed keywords

MUTANT PROTEIN; SERINE PROTEINASE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; SMOOTH MUSCLE FIBER; SWINE;

EID: 0030734794     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119803     Document Type: Article

References (39)

1. Bornfeldt, K.E., E.W. Raines, T. Nakano, L.M. Graves, E.G. Krebs, and R. Ross. 1993. Insulin-like growth factor I and platelet derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J. Clin. Invest. 93: 1266-1274.
2. Bornfeldt, K.E., H.J. Arnqvist, and L. Capron. 1993. In vivo proliferation of rat vascular smooth muscle in relation to diabetes mellitus: insulin-like growth factor I and insulin. Diabetologia. 35:104-108.
3. Clemmons, D.R., and D.S. Shaw. 1983. Variables controlling somatomedin production by cultured human fibroblasts. J. Cell. Physiol. 115:137-143.
4. Khorsondi, M.J., J.A. Fagin, J.C. Ginnella-Neto, J.S. Forrester, and B. Cercek. 1992. Regulation of insulin-like growth factor I and its receptor in rat aorta after balloon degradation: evidence for local bioactivity. J. Clin. Invest. 90:1926-1931.
5. Gockerman, A., J.I. Jones, T. Prevette, and D.R. Clemmons. 1995. Insulin like growth factor binding protein-2 inhibits smooth muscle cell migration response to IGF-I. Endocrinology. 136:4168-4173.
6. Delafontaine, P., H. Lou, and R.W. Alexander. 1991. Regulation of insulin-like growth factor I messenger RNA levels in vascular smooth muscle cells. Hypertension (Dallas). 18:742-747.
7. Padayatty, S.J., S. Orme, P.D. Zenobi, M.H. Strickland, P.E. Belchetz, and P.J. Grant. 1995. The effects of insulin-like growth factor-I on plasminogen activator inhibitor-1 synthesis and secretion: results from in vivo and in vitro studies. Thromb. Hemostasis. 74:1009-1013.
8. King, G.L., A.D. Goodman, S. Buzney, A. Moses, and C.R. Kahn. 1985. Receptors and growth promoting affects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta. J. Clin. Invest. 75:1028-1036.
9. Delafontaine, P., A. Anwar, H. Lou, and L. Ku. 1996. G-protein coupled and tyrosine kinase receptors: evidence that activation of the insulin-like growth factor I receptor is required for thrombin-induced mitogenesis of rat aortic smooth muscle cells. J. Clin. Invest. 97:139-147.
10. Clemmons, D.R., and J.J. Van Wyk. 1985. Evidence for a functional role of endogenously produced somatomedin-like peptides in the regulation of DNA synthesis in cultured human fibroblasts and porcine smooth muscle cells. J. Clin. Invest. 75:1914-1918.
11. Cohick, W.S., A. Gockerman, and D.R. Clemmons. 1993. Vascular smooth muscle cells synthesize two forms of insulin-like growth factor binding proteins which are regulated differently by the insulin like growth factors. J. Cell. Physiol. 157:52-60.
12. Duan, C.M., and D.R. Clemmons. 1996. Insulin like growth factor I (IGF-I) regulates IGF binding protein-5 synthesis through transcriptional activation of the gene in aortic smooth muscle cells. J. Biol. Chem. 271:4280-4288.
13. Ross, M., G.L. Francis, L. Szabo, J.C. Wallace, and F.J. Ballard. 1989. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-I and IGF-2 but not des-(1-3)-IGF-I. Biochem. J. 258:267-272.
14. Bourner, M.J., W.H. Bushy, N.R. Siegel, G.G. Krivi, R.H. McCusker, and D.R. Clemmons. 1992. Cloning and sequence determination of bovine insulin-like growth factor binding protein-2 (IGFBP-2): comparison of its structural and functional properties with IGFBP-1. J. Cell. Biochem. 48:215-226.
15. Arai, A., W.H. Busby, and D.R. Clemmons. 1996. Binding of insulin-like growth factor I or II to IGF binding protein enables it to bind to heparin or extracellular matrix. Endocrinology. 137:4571-4575.
16. Jones, J.I., A. Gockerman, W.H. Busby, C. Camacho-Hubner, and D.R. Clemmons. 1993. Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J. Cell Biol. 121:679-687.
17. Camacho-Hubner, C., W.H. Busby, R.H. McCusker, G. Wright, and D.R. Clemmons. 1992. Identification of the forms of insulin-like growth factor binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion. J. Biol. Chem. 267:11949-11956.
18. Hunkapiller, M.W., R.M. Hewick, R.J. Dreyer, and L.E. Hood. 1983. High sensitivity sequencing with a gas-phase sequencer. Methods Enyzmol. 91: 399-413.
19. Arai, T., S. Clarke, A. Parker, W.H. Busby, and D.R. Clemmons. 1996. Effect of substitution of specific amino acids in insulin like growth factor binding protein-5 on heparin binding and its change in affinity for IGF-I in response to heparin. J. Biol. Chem. 271:6099-6106.
20. Busby, W.H., D.G. Klapper, and D.R. Clemmons. 1988. Purification of a 31000 dalton insulin-like growth factor binding protein from human amniotic fluid. J. Biol. Chem. 263:14203-14210.
21. Ross, R. 1971. The smooth muscle cell: growth of smooth muscle in cultures and formation of elastic fibers. J. Cell Biol. 50:172-186.
22. Parker, A., A. Gockerman, W.H. Busby, and D.R. Clemmons. 1995. Properties of an insulin like growth factor binding protein 4 protease that is secreted by smooth muscle cells. Endocrinology. 135:2470-2476.
23. Clemmons, D.R. 1985. Exposure to platelet derived growth factor modulates porcine aortic smooth muscle cell response to somatomedin-C. Endocrinology. 117:77-83.
24. Arai, T., A. Arai, W.H. Busby, and D.R. Clemmons. 1994. Glycosaminoglycans inhibit degradation of insulin-like growth factor binding protein-5. Endocrinology. 135:2358-2363.
25. Jones, J.I., T. Prevette, A. Gockerman, and D.R. Clemmons. 1996. Binding of vitronectin to an aVB3 integrin is necessary for smooth muscle cells to migrate in response to IGF-I. Proc. Natl. Acad. Sci USA. 93:2462-2467.
26. Dong, Y., A. Skoulteki, and J. Pollard. 1993. Efficient DNA transfection of quiescent mammalian cells. Nucleic Acids Res. 21:1771-1772.
27. Nam, T.J., W.H. Busby, and D.R. Clemmons. 1994. Human fibroblasts secrete a serine protease that cleaves insulin like growth factor binding protein-5. Endocrinology. 135:1385-1391.
28. Andress, D.L., and R.S. Birnbaum. 1992. Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J. Biol. Chem. 267:22467-22472.
29. Mohan, S., C.M. Bautista, J. Wergedal, and D.J. Baylink. 1989. Isolation of inhibitory insulin-like growth factor (IGF) binding protein from bone cell conditioned medium: a potential local regulator of IGF action. Proc. Natl. Acad. Sci. USA. 86:8338-8342.
30. Coulouscou, J.M., and M. Shoyab. 1991. Purification of a colon cancer cell growth inhibitor and its identification as insulin-like growth factor binding protein-4. Cancer Res. 51:2813-2819.
31. Schmid, C., J. Rutishauser, I. Schlapfer, E.R. Froesch, and J. Zapf. 1991. Intact but not truncated insulin-like growth factor binding protein-3 blocks IGF-I induced stimulation of osteoblasts: control of IGF signaling to bone cells by IGFBP-3 specific proteolysis. Biochem. Biophys. Res. Commun. 179:579-585.
32. DeMellow, J.S.M., and R.C. Baxter. 1988. Growth hormone dependent insulin-like growth factor binding protein both inhibits and potentiates IGF-I stimulated DNA synthesis in skin fibroblasts. Biochem. Biophys. Res. Commun. 156:199-204.
33. Reeve, J.G., J. Schwanda, and N.M. Bleecham. 1993. IGFBP-2: an important regulator of insulin like growth factor action in human lung tissues. Growth Regul. 3:82-84.
34. Dollery, C.M., J.R. McEwan, and A.T. Henney. 1995. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 77:8653-8868.
35. Bautista, C.M., D.J. Baylink, and S. Mohan. 1991. Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: a potential candidate for fixing IGF-II in human bone. Biochem. Biophys. Res. Commun. 176:756-763.
36. Conover, C.A., and M.C. Keifer. 1993. Regulation of biological effect of endogenous insulin like growth factor binding protein 5 in human osteoblast cells. J. Clin. Endocrinol. Metab. 76:1153-1159.
37. Van Leeuwen, R.T.J. 1996. Extracellular proteolysis and the migrating vascular smooth muscle cell. Fibrinoloysis. 10:59-74.
38. Clowes, A.W., M.M. Clowes, Y.P. Au, M.A. Reidy, and D. Belin. 1990. Smooth muscle cells express urokinase during mitogenesis and tissue type plasminogen activator during migration in injured rat carotid artery. Circ. Res. 67: 61-67.
39. Carmeliet, P., L. Moons, V. Plopis, E. Plow, and D. Collen. 1997. Impaired arterial neontima formation in mice with disruption of the plasminogen gene. J. Clin. Invest. 99:200-208.